Bicara Therapeutics (NASDAQ:BCAX) Hits New 12-Month Low – Here’s Why

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $19.47 and last traded at $19.68, with a volume of 12127 shares traded. The stock had previously closed at $20.30.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Morgan Stanley assumed coverage on Bicara Therapeutics in a research report on Tuesday. They issued an “overweight” rating and a $35.00 price target for the company. TD Cowen began coverage on Bicara Therapeutics in a research report on Tuesday. They issued a “buy” rating for the company. Stifel Nicolaus began coverage on Bicara Therapeutics in a research report on Tuesday. They set a “buy” rating and a $47.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on Bicara Therapeutics in a research report on Tuesday. They set an “overweight” rating on the stock.

Bicara Therapeutics Trading Up 2.2 %

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, Director Ra Capital Management, L.P. bought 1,833,000 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, September 16th. The shares were bought at an average cost of $18.00 per share, with a total value of $32,994,000.00. Following the transaction, the director now directly owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder James E. Flynn acquired 70,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were acquired at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the acquisition, the insider now owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the acquisition, the director now directly owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.